本文選題：冠心病　切入點(diǎn)：前蛋白轉(zhuǎn)化酶枯草溶菌素　出處：《中國動(dòng)脈硬化雜志》2017年04期

【摘要】：目的探討冠心病患者血清前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)與小而密低密度脂蛋白膽固醇(sd LDLC)的關(guān)系。方法收集2014年3月至2014年12月在山西醫(yī)科大學(xué)第一醫(yī)院住院且行冠狀動(dòng)脈造影術(shù)確診為冠心病的患者100例作為冠心病組,同期健康體檢者67例作為對(duì)照組。Lipoprint脂蛋白分析儀檢測(cè)LDLC顆粒大小、sd LDLC顆粒數(shù)及sd LDLC所占LDLC的百分比(簡稱sd LDLC百分比);酶聯(lián)免疫吸附法測(cè)定血清PCSK9。結(jié)果冠心病組LDLC顆粒大小低于對(duì)照組(264.07±6.78比267.37±5.15,P0.01),sd LDLC顆粒數(shù)多于對(duì)照組(5.0±9.5比4.0±5.0,P0.05),sd LDLC百分比大于對(duì)照組(5.95%±10.50%比3.70%±5.85%,P0.01)。冠心病組血清PCSK9顯著高于對(duì)照組(15.48μg/L比14.95μg/L,U=-2.74,P=0.006)。冠心病組血清PCSK9與sd LDLC百分比、LDLC呈正相關(guān)(r=0.212,P=0.034;r=0.202,P=0.032)。結(jié)論冠心病患者血清PCSK9與sd LDLC百分比呈正相關(guān),抑制PCSK9可以預(yù)防冠心病。
[Abstract]:Objective to investigate the relationship between serum proprotein converting enzyme (PCSK9) and small and dense low density lipoprotein cholesterol (LDLC) in patients with coronary heart disease (CHD). Methods from March 2014 to December 2014, the patients were hospitalized and performed in the first Hospital of Shanxi Medical University. 100 cases of coronary artery disease diagnosed by coronary angiography were used as coronary heart disease group. In the same period, 67 healthy persons served as control group. Lipoprint lipoprotein analyzer was used to detect the size of LDLC particles and the percentage of SD LDLC in LDLC. Elisa was used to detect serum PCSK9. Results in coronary heart disease group, the number of SD LDLC particles and the percentage of SD LDLC in LDLC were determined by enzyme-linked immunosorbent assay (Elisa). The LDLC particle size was lower than that of the control group (264.07 鹵6.78 vs 267.37 鹵5.15 渭 g / L = 267.37 鹵5.15 渭 g / L vs 5.0 鹵9.5 vs 4.0 鹵5.0 vs 4.0 鹵5.0 vs 4.0 鹵5.0) respectively. The percentage of serum PCSK9 in coronary heart disease group was significantly higher than that in control group (5.95% 鹵10.50% vs 3.70% 鹵5.70% 鹵5.70% 鹵5.70% vs 3.70% 鹵5.70%, P 0.01). The serum PCSK9 in CHD group was significantly higher than that in control group (15.48 渭 g / L vs 14.95 渭 g / L vs 14.95 渭 g / L vs 2.74 渭 g / L vs 14.95 渭 g / L vs 2.74 渭 g / L, P 0.006). Conclusion there is a positive correlation between the percentage of serum PCSK9 and SD LDLC in patients with coronary heart disease. Inhibition of PCSK9 can prevent coronary heart disease.
【作者單位】： 山西醫(yī)科大學(xué)第一臨床醫(yī)學(xué)院心內(nèi)科;山西醫(yī)科大學(xué)第二臨床醫(yī)學(xué)院心內(nèi)科山西省臨床心血管藥理實(shí)驗(yàn)室;
【分類號(hào)】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前3條

1 龔慧琴;吳琪;文紅艷;劉錄山;;前蛋白轉(zhuǎn)化酶枯草溶菌素9基因多態(tài)性的臨床研究進(jìn)展[J];中國動(dòng)脈硬化雜志;2012年04期

2 邱瑜;文紅艷;;前蛋白轉(zhuǎn)化酶枯草溶菌素9基因與冠心病[J];社區(qū)醫(yī)學(xué)雜志;2010年01期

3 ;[J];;年期

相關(guān)會(huì)議論文 前1條

1 李建軍;;PCSK9:調(diào)節(jié)動(dòng)脈粥樣硬化的新靶點(diǎn)[A];第十二屆全國脂質(zhì)與脂蛋白學(xué)術(shù)會(huì)議論文匯編[C];2014年

，

本文編號(hào)：1666908